Amgen and AstraZeneca’s Tezspire has delivered a significant phase 3 clinical win in eosinophilic esophagitis, intensifying competition with Sanofi and Regeneron’s Dupixent. The companies announced that the phase 3 CROSSING trial hit
MoreThe U.S. Court of Appeals for the Fifth Circuit has rejected a major pharmaceutical industry lawsuit challenging Medicare drug price negotiations under the Inflation Reduction Act. The appeals court affirmed a lower
MorePublicis Health has appointed Stephen Farquhar as its new chief executive officer, with the leadership transition taking effect on February 1. Farquhar steps into the role succeeding Alexandra von Plato, who has
MoreRoche has been accelerating its obesity pipeline strategy through a series of high-value partnerships designed to compete in the fast-growing weight-loss drug market. The Swiss pharmaceutical giant struck a deal worth up
MoreTeva Pharmaceuticals (TEVA) has emerged as the stalking horse bidder for bankrupt BioXcel Therapeutics’ neuroscience portfolio in a deal worth up to $125 million. Connecticut-based BioXcel filed for Chapter 11 bankruptcy protection
MoreTakeda Pharmaceutical (TAK) has secured FDA approval for Mimrylo, a first-of-its-kind therapy targeting polycythemia vera, a rare and potentially life-threatening blood cancer. Polycythemia vera affects approximately 90,000 people in the United States
MoreCencora, one of the largest pharmaceutical distributors in the United States, is deploying artificial intelligence to tackle persistent compliance gaps under the Drug Supply Chain Security Act. Gregg Gorniak, VP of manufacturer
MoreEli Lilly (LLY) has secured FDA approval to expand the label for its blockbuster diabetes drug Mounjaro to cover cardiovascular risk reduction in at-risk adults with type 2 diabetes. The approval allows
MoreCytokinetics, Incorporated (Nasdaq: CYTK) has presented a broad package of new clinical data for MYQORZO at the European Society of Cardiology Heart Failure 2026 Congress. The presentations reinforced the clinical profile of
MoreRayzeBio, a Bristol Myers Squibb company, plans to invest more than $173 million in central Indiana operations and build a major new manufacturing facility. The company will establish an approximately 450,000-square-foot facility
More
